ATE293168T1 - Thrombin mutanten - Google Patents

Thrombin mutanten

Info

Publication number
ATE293168T1
ATE293168T1 AT95901894T AT95901894T ATE293168T1 AT E293168 T1 ATE293168 T1 AT E293168T1 AT 95901894 T AT95901894 T AT 95901894T AT 95901894 T AT95901894 T AT 95901894T AT E293168 T1 ATE293168 T1 AT E293168T1
Authority
AT
Austria
Prior art keywords
nps
protein
useful
clotting
fibrinogen
Prior art date
Application number
AT95901894T
Other languages
English (en)
Inventor
Craig S Gibbs
Lawrence L K Leung
Manuel Tsiang
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ATE293168T1 publication Critical patent/ATE293168T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95901894T 1993-11-12 1994-11-14 Thrombin mutanten ATE293168T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15265793A 1993-11-12 1993-11-12
US25803894A 1994-06-10 1994-06-10
PCT/US1994/013104 WO1995013385A2 (en) 1993-11-12 1994-11-14 Thrombin mutants

Publications (1)

Publication Number Publication Date
ATE293168T1 true ATE293168T1 (de) 2005-04-15

Family

ID=26849740

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95901894T ATE293168T1 (de) 1993-11-12 1994-11-14 Thrombin mutanten

Country Status (9)

Country Link
US (1) US6110721A (de)
EP (1) EP0728210B1 (de)
JP (2) JPH09509045A (de)
CN (1) CN1103815C (de)
AT (1) ATE293168T1 (de)
AU (1) AU1096595A (de)
DE (1) DE69434332T2 (de)
ES (1) ES2240972T3 (de)
WO (1) WO1995013385A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT404357B (de) * 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
WO2000062828A1 (en) * 1996-04-30 2000-10-26 Medtronic, Inc. Autologous fibrin sealant and method for making the same
WO1997040864A1 (en) * 1996-04-30 1997-11-06 Medtronic, Inc. Method for making autologous fibrin sealant
US6270973B1 (en) * 1998-03-13 2001-08-07 Promega Corporation Multiplex method for nucleic acid detection
US20030069601A1 (en) * 1998-12-15 2003-04-10 Closys Corporation Clotting cascade initiating apparatus and methods of use
DE10012732A1 (de) * 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US6423826B1 (en) * 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6506365B1 (en) * 2000-09-25 2003-01-14 Baxter Aktiengesellschaft Fibrin/fibrinogen binding conjugate
EP2322648A1 (de) * 2000-09-26 2011-05-18 Duke University RNA-Aptamere und Verfahren zu ihrer Identifizierung
US6942880B1 (en) * 2001-04-09 2005-09-13 Medtronic, Inc. Autologous platelet gel having beneficial geometric shapes and methods of making the same
IL159053A0 (en) * 2001-05-25 2004-05-12 Univ Duke Modulators of pharmacological agents
US6706512B2 (en) * 2001-06-08 2004-03-16 Emory University Antithrombotic thrombin variants
CA2820537C (en) 2003-04-23 2015-10-20 Valeritas, Inc. Hydraulically actuated pump for fluid administration
EP1734116A4 (de) * 2004-03-19 2007-09-05 Chisso Corp Thrombinderivate und diese enthaltende medizinische zusammensetzung
PT1745062E (pt) * 2004-04-22 2014-07-11 Regado Biosciences Inc Moduladores melhorados de fatores de coagulação
JP2007159401A (ja) * 2004-05-07 2007-06-28 Precision System Science Co Ltd 改変タンパク質の作製方法
WO2006014425A1 (en) 2004-07-02 2006-02-09 Biovalve Technologies, Inc. Methods and devices for delivering glp-1 and uses thereof
CA2644926A1 (en) * 2006-03-06 2007-09-13 Humagene, Inc. A method for the preparation of recombinant human thrombin and fibrinogen
RU2438719C2 (ru) 2006-03-30 2012-01-10 ВАЛЕРИТАС Инк. Многокартриджное устройство для введения жидкости
WO2007127834A2 (en) * 2006-04-26 2007-11-08 Medtronic, Inc. Compositions and methods of preparation thereof
CN101535479A (zh) * 2006-11-15 2009-09-16 智索株式会社 凝血酶突变体
US10231721B2 (en) 2010-06-24 2019-03-19 St. Croix Surgical Systems, Llc Failsafe percutaneous wound barrier
US20130309753A1 (en) * 2012-05-16 2013-11-21 Saint Louis University Recombinant auto-activating protease precursors
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
JP7407511B2 (ja) * 2015-10-08 2024-01-04 ネクター セラピューティクス ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用
US20200054719A1 (en) * 2016-11-02 2020-02-20 Erik Ian Tucker E-we thrombin analog and fibrinolytic combination
AU2018270926C1 (en) 2017-05-15 2022-10-27 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
US20230036793A1 (en) * 2019-12-12 2023-02-02 Iltoo Pharma Interleukin 2 chimeric constructs
CN111676208B (zh) * 2020-06-17 2021-11-02 江苏师范大学 一种定点突变改造的β-半乳糖苷酶及其构造方法
CN112062833A (zh) * 2020-10-09 2020-12-11 国药集团武汉血液制品有限公司 一种从血浆组分ⅳ沉淀中提取人血白蛋白的方法
CN115558015B (zh) * 2022-10-12 2024-01-19 生工生物工程（上海）股份有限公司 一种从gst融合蛋白酶切后的产物中纯化无gst标签的目的蛋白的方法和产品

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4303592A (en) * 1980-01-09 1981-12-01 Center For Blood Research, Inc. Amidinophenylmethylsulfonylfluoride
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) * 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5352664A (en) * 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
US5147638A (en) * 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
US5304482A (en) * 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
FI923347A0 (fi) * 1990-01-26 1992-07-23 Immuno Ag Blodfaktorer producerade med rekombinant-dna-teknik och foerfarande foer expression av naemnda blodfaktorer samt i naemnda foerfarande anvaenda rekombinanta kokoppvirus.
US5246850A (en) * 1990-07-31 1993-09-21 Genentech, Inc. DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
WO1993009807A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
EP1449849A3 (de) * 1992-02-05 2006-01-25 Paion Deutschland GmbH Protease-resistentes Thrombomodulinanalog
NZ253556A (en) * 1992-06-03 1995-11-27 Genentech Inc Tissue plasminogen activator (t-pa) variants (with extended circulatory half-life and/or potency); preparation, compositions, host cells, dna sequences, and expression vehicles thereof

Also Published As

Publication number Publication date
EP0728210B1 (de) 2005-04-13
EP0728210A1 (de) 1996-08-28
AU1096595A (en) 1995-05-29
DE69434332D1 (de) 2005-05-19
CN1139455A (zh) 1997-01-01
JP2007312777A (ja) 2007-12-06
ES2240972T3 (es) 2005-10-16
DE69434332T2 (de) 2006-02-02
US6110721A (en) 2000-08-29
WO1995013385A3 (en) 1996-02-01
JPH09509045A (ja) 1997-09-16
WO1995013385A2 (en) 1995-05-18
CN1103815C (zh) 2003-03-26

Similar Documents

Publication Publication Date Title
DE69434332D1 (de) Thrombin mutanten
Richardson et al. Chemotaxis for human monocytes by fibrinogen‐derived peptides
Mazzucco et al. Platelet‐rich plasma and platelet gel preparation using Plateltex®
DK1294414T3 (da) Præparat og fremgangsmåde til heling og regenerering af brusk og andre væv
AU2004207261B2 (en) Autologous or homologous coagulant produced from anticoagulated whole blood
DK0956339T3 (da) Rekombinant vaskulær endotelcellevækstfaktor D (VEGF-D)
PT98113A (pt) Processo para a preparacao de proteinas de fusao com uma fraccao de imunoglobulina
DK0654078T3 (da) Thrombinblodfraktion til anvendelse i en medicinsk procedure
AU4159185A (en) Method of inhibiting binding of von willebrand factor to human platelets and inducing interaction of platelets with vessel walls
DE69132352D1 (de) Protein-antagonisten der blut-koagulation und ihre verwendung
DE3587724D1 (de) Antikörper verwendende diagnostische Methoden.
DE59109048D1 (de) Inhibitoren zur antikoagulierenden Vorbehandung von Blutproben
DK1124589T3 (da) Formulering af fibrin-vævsklæber og fremgangsmåde til fremstilling af denne
HU9201552D0 (en) Medical preparation for the neutralization of procoagulant activity cused by tumorous cells
Bajwa et al. Fibrinolytic and fibrinogen clotting enzymes present in the venoms of western diamondback rattlesnake, Crotalus atrox, eastern diamondback rattlesnake, Crotalus adamanteus, and southern Pacific rattlesnake, Crotalus viridis helleri
BR9810242A (pt) Composições úteis como selante de fibrina
Seybold et al. Osteogenic differentiation of human mesenchymal stromal cells is promoted by a leukocytes containing fibrin matrix
Barlow et al. Immunochemical identification of ancrod (A38414) and reptilase (defibrase)
DE59309254D1 (de) Verwendung von Prothrombinfragmenten
Perutelli et al. Abnormalities of plasma von Willebrand factor multimeric structure induced by extracorporeal circulation
Banerjee et al. Studies of actions of snake venoms on blood coagulation II. Electrophoretic analysis of venoms of Viperidae, Crotalidae, Elapidae and Hydrophidae
Becker Seminars in Thrombosis, Thrombolysis, and Vascular Biology: 6. Procoagulant States
Komp et al. The origin of cerebrospinal fluid procoagulant activity
Beckmann et al. Fibronectin (FN) decreases the stimulatory effect of fibrin and fibrinogen fragment FCB-2 on plasmin formation by tissue plasminogen activator (t-PA)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties